Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 14/20 | 0.66 |
| ▸ | MMP2 | P08253 | 14/20 | 0.66 |
| ▸ | MMP9 | P14780 | 14/20 | 0.66 |
| ▸ | MAOB | P27338 | 3/20 | 0.65 |
| ▸ | KDR | P35968 | 2/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3546322 | 1.00 | MMP1 (0.66) | MMP1MMP2MMP9MAOBKDR | |
| SCHEMBL11796823 | 0.87 | KDR (0.64) | MMP1MMP2MMP9MAOBKDR | |
| SCHEMBL11803033 | 0.85 | KDR (0.70) | KDRHDAC1HDAC8HDAC6MEN1 | |
| SCHEMBL11796925 | 0.83 | HDAC6 (0.74) | MMP1MMP2MMP9KDRHDAC1 | |
| SCHEMBL13547728 | 0.82 | MAPT (0.67) | KDRHDAC1HDAC8HDAC6MEN1 | |
| SCHEMBL3544621 | 0.81 | LMNA (0.53) | KDRLMNAMAPTNPSR1 | |
| SCHEMBL3544626 | 0.81 | LMNA (0.53) | KDRLMNAMAPTNPSR1 | |
| SCHEMBL28316655 | 0.79 | MMP1 (1.00) | MMP1MMP2MMP9MAOB | |
| SCHEMBL13675773 | 0.79 | KDR (0.68) | MAOBKDRHDAC1HDAC8HDAC6 | |
| SCHEMBL1791120 | 0.79 | NOTUM (0.54) | MAOBKDRHDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652041-B2 | 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20060160803-A1 | Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160803-A1 | Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity | MAP3K21, HIPK4, MAP3K20 | MMP1 2962/4885MMP2 1919/4885MMP9 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.